Trusted by:

clients clients clients clients clients clients clients clients clients clients
Newswise:Video Embedded fda-changes-to-lab-tests-regulations-livestream-expert-panel
VIDEO
Released: 25-Jul-2024 10:05 AM EDT
FDA Changes to Laboratory Developed Test Regulation: Livestreamed Expert Panel
Newswise

Live from the annual conference of the Association for Diagnostics & Laboratory Medicine (ADLM, formerly AACC), experts will discuss how the new FDA rule on laboratory developed tests will hinder patient care. This rule will place these tests under duplicative FDA oversight, even though laboratory developed tests are already regulated by the Centers for Medicare & Medicaid Services. This will force many labs to stop performing these essential tests, which play a critical role in diagnosing rare disorders, such as inherited genetic conditions in newborns.

       
Released: 23-Jul-2024 8:55 AM EDT
Dual action antibiotic could make bacterial resistance nearly impossible
University of Illinois Chicago

New drug that disrupts two cellular targets would make it much harder for bacteria to evolve resistance

Released: 18-Jul-2024 4:05 PM EDT
Hairy cell leukemia variant and WHO classification correspondence Re: 5th edition WHO classification haematolymphoid tumors: lymphoid neoplasms
University of New Mexico Comprehensive Cancer Center

In 2022, Alaggio and colleagues revised the WHO Classification of Haematolymphoid Tumors resulting in elimination of the provisional diagnostic categories of Hairy Cell Leukemia Variant (HCLv) and B Prolymphocytic Leukemia.

Newswise: Why the Most Prescribed Chemotherapy Drug Can Cause Serious Heart Damage
Released: 17-Jul-2024 2:00 PM EDT
Why the Most Prescribed Chemotherapy Drug Can Cause Serious Heart Damage
Tufts University

There’s still much to learn about how doxorubicin, a 50-year-old chemotherapy drug, causes its most concerning side effects. While responsible for saving many lives, this treatment sometimes causes cardiac damage that stiffens the heart and puts a subset of patients at risk for future heart failure. To better understand and potentially control such complications, Tufts University School of Medicine and Tufts Graduate School of Biomedical Sciences researchers have isolated the immune cells that become overactive when patients take doxorubicin.

   
Newswise: Diseño de opioides más seguros
Released: 17-Jul-2024 11:00 AM EDT
Diseño de opioides más seguros
American Chemical Society (ACS)

En un estudio publicado en ACS Central Science, los investigadores han identificado una estrategia para diseñar opioides más seguros. Han demostrado que un opioide experimental, que se une a un sitio no convencional del receptor, suprime el dolor en modelos animales con menos efectos secundarios, especialmente los vinculados a sobredosis fatales.

   
Newswise: Psilocybin generates psychedelic experience by disrupting brain network
14-Jul-2024 11:00 AM EDT
Psilocybin generates psychedelic experience by disrupting brain network
Washington University in St. Louis

Researchers at Washington University School of Medicine in St. Louis report that psilocybin, the active ingredient in magic mushrooms, destabilizes a critical network of brain areas involved in introspective thinking. The findings provide a neurobiological explanation for the drug’s mind-bending effects.

Newswise: Unraveling the DNA mystique of Saposhnikovia divaricata: new horizons in herbal medicine
Released: 17-Jul-2024 9:05 AM EDT
Unraveling the DNA mystique of Saposhnikovia divaricata: new horizons in herbal medicine
Chinese Academy of Sciences

In a pioneering study, scientists have decoded the genetic blueprint of Saposhnikovia divaricata, a traditional medicinal herb. The research provides a detailed genome sequence, shedding light on the plant’s evolutionary adaptations and the genetic foundations of its therapeutic benefits.

   
Newswise: Designing safer opioids
12-Jul-2024 8:00 AM EDT
Designing safer opioids
American Chemical Society (ACS)

In a study in ACS Central Science, researchers have identified a strategy to design safer opioids. They showed that an experimental opioid, which binds to an unconventional spot in the receptor, suppresses pain in animal models with fewer side effects — most notably those linked to fatal overdoses.

   
Newswise: Engineered nanovesicles from activated neutrophils show promise in treating infected wounds
Released: 17-Jul-2024 5:05 AM EDT
Engineered nanovesicles from activated neutrophils show promise in treating infected wounds
Chinese Academy of Sciences

A recent study has developed nanovesicles (NVs) from activated neutrophils, showcasing their ability to perform molecular debridement and accelerate healing in infectious wounds. This novel method significantly enhances treatment effectiveness, particularly for stubborn diabetic wounds, by targeting and neutralizing deep tissue pathogens.

   

Not for public release

This news release is embargoed until 11-Jul-2024 7:05 PM EDT Released to reporters: 11-Jul-2024 8:05 AM EDT

A reporter's PressPass is required to access this story until the embargo expires on 11-Jul-2024 7:05 PM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.


close
2.40101